• CLSI C56-A

CLSI C56-A

Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline, C56AE

Clinical and Laboratory Standards Institute, 07/01/2012

Publisher: CLSI

File Format: PDF

$90.00$180.00


Published:01/07/2012

Pages:64

File Size:1 file , 1.9 MB

Note:This product is unavailable in Russia, Belarus

Clinical and Laboratory Standards Institute document C56-A - Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline focuses on the intended usefulness and challenging issues of hemolysis, icterus, and lipemia/turbidity (HIL) indices as estimates of interference that may impact the validity and clinical utility of reportable patient results. C56 is closely aligned with CLSI document EP071; thus, the basic concepts for interference testing are briefly discussed in C56 to gain an understanding of the process by which HIL alert indices are established. Automated HIL systems currently available from various manufacturers are also described. This document enhances the continuous education of health care personnel by explaining the mechanisms of HIL interference, which in some cases include the noncorrelation of visual and (semi)quantitative HIL indices, the strengths and limitations of HIL measurements, and the verification of HIL indices in the clinical laboratory.

More CLSI standard pdf

CLSI I/LA26-A

CLSI I/LA26-A

Performance of Single Cell Immune Response Assays; Approved Guideline, ILA26A

$137.00 $275.76

CLSI GP43-A4

CLSI GP43-A4

Procedures for the Collection of Arterial Blood Specimens; Approved Standard, GP43A4E

$125.00 $251.43

CLSI EP05-A2

CLSI EP05-A2

Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline, EP05A2E

$116.00 $233.97

CLSI POCT14-A

CLSI POCT14-A

Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline, POCT14AE

$90.00 $180.00